In Vitro Interaction between Isavuconazole and Tacrolimus, Cyclosporin A, or Sirolimus against Aspergillus Species

In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY Antifungal Surveillance Program, 2017–2018

(2020) Shawn A. Messer et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Antifungal combinations in Mucorales: a microbiological perspective

(2019) Patrick Schwarz et al.   MYCOSES

In vitro interactions between isavuconazole and tacrolimus, cyclosporin A or sirolimus against Mucorales

(2019) Patrick Schwarz et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Harnessing calcineurin-FK506-FKBP12 crystal structures from invasive fungal pathogens to develop antifungal agents

(2019) Praveen R. Juvvadi et al.   Nature Communications

Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline

(2018) A.J. Ullmann et al.   CLINICAL MICROBIOLOGY AND INFECTION

In vitro and in vivo assessment of FK506 analogs as novel antifungal drug candidates

(2018) Yeonseon Lee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Targeting efflux pumps to overcome antifungal drug resistance

(2016) Ann R Holmes et al.   Future Medicinal Chemistry

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial

(2016) Johan A Maertens et al.   LANCET

In VitroInteractions of Antifungal Agents and Tacrolimus against Aspergillus Biofilms

(2015) Lujuan Gao et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Invasive Aspergillosis After Kidney Transplant: Case-Control Study

(2015) Line Heylen et al.   CLINICAL INFECTIOUS DISEASES

Azole Resistance inAspergillus fumigatus: Can We Retain the Clinical Use of Mold-Active Antifungal Azoles?

(2015) Paul E. Verweij et al.   CLINICAL INFECTIOUS DISEASES

Antifungal activity of compounds targeting the Hsp90-calcineurin pathway against various mould species: Table 1.

(2015) Frédéric Lamoth et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Multi-azole-resistant Aspergillus fumigatus in the environment in Tanzania

(2014) A. Chowdhary et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Current and emerging strategies for the prevention of graft-versus-host disease

(2014) Sung Won Choi et al.   Nature Reviews Clinical Oncology

Determination of Isavuconazole Susceptibility of Aspergillus and Candida Species by the EUCAST Method

(2013) Susan J. Howard et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroSusceptibility of Aspergillus fumigatus to Isavuconazole: Correlation with Itraconazole, Voriconazole, and Posaconazole

(2013) Lea Gregson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Correction: Emergence of Azole-Resistant Aspergillus fumigatus Strains due to Agricultural Azole Use Creates an Increasing Threat to Human Health

(2013) Anuradha Chowdhary et al.   PLoS Pathogens

Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry

(2012) William J. Steinbach et al.   JOURNAL OF INFECTION

Tacrolimus Enhances the Potency of Posaconazole Against Rhizopus oryzae In Vitro and in an Experimental Model of Mucormycosis

(2012) R. E. Lewis et al.   JOURNAL OF INFECTIOUS DISEASES

Azole Resistance in Aspergillus fumigatus Isolates from the ARTEMIS Global Surveillance Study Is Primarily Due to the TR/L98H Mutation in thecyp51AGene

(2011) Shawn R. Lockhart et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro interaction of posaconazole with calcineurin inhibitors and sirolimus against zygomycetes

(2010) S. Narreddy et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In Vitro Interactions between Antifungals and Immunosuppressive Drugs against Zygomycetes

(2009) E. Dannaoui et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A Risk Profile for Invasive Aspergillosis in Liver Transplant Recipients

(2009) M. Rosenhagen et al.   INFECTION

Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?

(2009) Paul E Verweij et al.   LANCET INFECTIOUS DISEASES

Aspergillosis

(2009) Brahm H. Segal   NEW ENGLAND JOURNAL OF MEDICINE

In vitro interaction between azoles and cyclosporin A against clinical isolates of Candida albicans determined by the chequerboard method and time-kill curves

(2008) Y. Li et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY